Medable, founded in 2015, builds an end-to-end cloud platform for clinical development that combines agentic AI with tools for running clinical trials. Its technology connects pharmaceutical sponsors, contract research organisations, healthcare providers and patients across trials conducted globally. The company was founded by Dr. Michelle Longmire, a physician-scientist, after her own experience of barriers to patient access in clinical research.
Technical work spans agentic AI and AI-powered agent platforms, cloud computing, and clinical trial management software. Product areas include electronic Clinical Outcome Assessment (eCOA) tools, decentralized clinical trial (DCT) solutions for remote and hybrid trial conduct, study management tools across sponsors, CROs, providers and patients, and Studio, a study-building product that, combined with AI, is reported to enable sponsors to build studies up to 35 times faster.
Medable serves the pharmaceutical, biotechnology, CRO and healthcare provider sectors, with particular application in clinical research, oncology and vaccines. Its DCT offering has been recognised as a Leader by Everest Group, and the company has received a Prix Galien award for Best Digital Platform. Stated goals for the industry include one-day study startup, one-day patient enrollment and one-year study conduct.
